Protein tyrosine kinases : from inhibitors to useful drugs

著者

• Fabbro, D.
• McCormick, Frank

書誌事項

Protein tyrosine kinases : from inhibitors to useful drugs

edited by Doriano Fabbro and Frank McCormick

（Cancer drug discovery and development）

Humana Press, c2006

注記

Includes bibliographical references and index

HTTP:URL=http://www.loc.gov/catdir/toc/ecip059/2005006248.html Information=Table of contents

内容説明・目次

内容説明

Leading researchers, from the Novartis group that pioneered Gleevec/Glivec (TM) and around the world, comprehensively survey the state of the art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made towards generating "selective" low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for testing protein kinase inhibitors with antitumor activity and the utility of different methods in the drug discovery and development process for determining "on-target" vs "off-target" effects of kinase inhibitors.

目次

Protein Tyrosine Kinases as Targets for Cancer and Other Indications Mark Pearson, Carlos Garcia-Echeverria, and Doriano Fabbro Inhibitors of Signaling Interfaces: Targeting Src Homology 2 Domains in Drug Discovery Carlos Garcia-Echeverria PI3-Kinase Inhibition: A Target for Therapeutic Intervention Peter M. Finan and Stephen G. Ward Src as a Target for Pharmaceutical Intervention: Potential and Limitations Mira Susa, Martin Missbach, Rainer Gamse, Michaela Kneissel, Thomas Buhl, Jurg A. Gasser, Markus Glatt, Terence O'Reilly, Anna Teti, and Jonathan Green Activated FLT3 Receptor Tyrosine Kinase as a Therapeutic Target in Leukemia Blanca Scheijen and James D. Griffin JAK Kinases in Leukemias, Lymphomas, and Multiple Myeloma Renate Burger and Martin Gramatzki Glivec (R) (Gleevec (R), Imatinib, STI571): A Targeted Therapy for Chronic Myelogenous Leukemia Elisabeth Buchdunger and Renaud Capedeville Platelet-Derived Growth Factor: Normal Function, Role in Disease, and Application of PDGF Antagonists Tobias Sjoeblom, Kristian Pietras, Arne OEstman, and Carl-Henrik Heldin Structural Biology of Protein Tyrosine Kinases Sandra W. Cowan-Jacob, Paul Ramage, Wilhelm Stark, Gabriele Fendrich, and Wolfgang Jahnke Testing of Signal Transduction Inhibitors in Animal Models of Cancer Terence O'Reilly and Robert Cozens Phosphoproteomics in Drug Discovery and Development Michel F. Moran, Jarrod A. Marto, Cynthia J. Brame, Olga Ornatsky, Mark M. Ross, Leticia M. Toledo-Sherman, Alfredo C. Castro, Brett Larsen, Henry Duewel, Christopher Hosfield, Christopher Orsi, Thodoros Topaloglou, Daniel Figeys, Jarrod A. Caldwell-Busby, and David R. Stover Index

「Nielsen BookData」 より

詳細情報

• NII書誌ID(NCID): BA74650695
• ISBN:
  • 158829384X
• LCCN: 2005006248
• 出版国コード: us
• タイトル言語コード: eng
• 本文言語コード: eng
• 出版地: Totowa, N.J.
• ページ数/冊数: xiii, 290 p.
• 大きさ: 24 cm
• 分類:
  • LCC : RC271.P76
  • DC22 : 616.99/4061
• 件名:
  • LCSH : Protein-tyrosine kinase -- Inhibitors -- Therapeutic use
  • LCSH : Cancer -- Chemotherapy
• 親書誌ID:
  • BA36585533